Go Deep
Candel Therapeutics, Inc.
Candel Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,064 | -6.3 | 5.62 | 0.39 | 882.82 |
| Oct 2026 | 18,197 | -6.2 | 5.50 | 0.39 | 861.17 |
| Oct 2026 | 18,302 | -6.2 | 5.41 | 0.39 | 846.10 |
| Oct 2026 | 18,779 | -5.6 | 4.97 | 0.39 | 775.72 |
| Oct 2026 | 18,765 | -5.6 | 4.98 | 0.39 | 778.44 |
| Oct 2026 | 18,481 | -5.9 | 5.24 | 0.39 | 819.21 |
| Oct 2026 | 18,660 | -5.7 | 5.08 | 0.39 | 791.65 |
| Oct 2026 | 18,653 | -5.7 | 5.08 | 0.39 | 791.00 |
Candel Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -38,905,000.0 | -8,861,000.0 | -29,496,000.0 | -11,269,000.0 |
| EPS | -0.5 | -0.1 | -0.5 | -0.2 |
Candel Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 125,000.0 | — |
| Net Profit | -38,182,000.0 | -55,177,000.0 | -37,939,000.0 | -18,794,000.0 | — |
| EPS | -0.7 | -1.7 | -1.3 | -0.7 | — |
Candel Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 125,195,000.0 | 106,866,000.0 | 41,201,000.0 | 77,691,000.0 | — |
| Total Liabilities | 73,273,000.0 | 40,539,000.0 | 28,456,000.0 | 29,977,000.0 | — |
| Total Equity | 51,922,000.0 | 66,327,000.0 | 12,745,000.0 | 47,714,000.0 | — |
Owes vs Owns
Candel Therapeutics, Inc. owed $0.39 for every $1 it owned in Jun 2026, up from $0.39 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.39× | 0.59× | 0.38× | 0.69× | 0.39× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Candel Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 95.6%Fixed assets (tangible) 2.6%Other assets 1.7%
How it's funded — Dec 2025
Long-term debt 37.6%Payables 0.9%Other liabilities 19.6%Shareholders' equity 41.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 119.7 | 102.7 | 35.4 | 70.1 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 3.3 | 2.7 | 4.0 | 5.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 2.2 | 1.5 | 1.8 | 2.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.4 | 9.9 | 8.9 | 0.5 |
| Long-term debt | 47.1 | 2.6 | 12.4 | 20.9 |
| Payables | 1.1 | 0.2 | 0.4 | 0.4 |
| Other liabilities | 24.6 | 27.8 | 6.8 | 8.3 |
| Shareholders' equity | 51.9 | 66.3 | 12.7 | 47.7 |
| Net tangible assets | 51.9 | 66.3 | 12.7 | 47.7 |
Candel Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -38,311,000.0 | -27,023,000.0 | -34,244,000.0 | -31,419,000.0 | — |
| Investing Activities | -560,000.0 | -16,000.0 | -280,000.0 | -1,297,000.0 | — |
| Financing Activities | 56,098,000.0 | 94,280,000.0 | -121,000.0 | 19,974,000.0 | — |